{"id":"W1976585485","doi":"10.1016/s1470-2045(11)70037-7","title":"Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Charles-Le Moyne; Centre hospitalier universitaire de Québec","funders":"","keywords":"Bevacizumab; Metastatic breast cancer; Medicine; Paclitaxel; Placebo; HER2 negative; Oncology; Breast cancer; Internal medicine; Open label; Double blind; Cancer; Clinical trial; Chemotherapy; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001585504,0.002375006,0.004460104,0.0007854956,0.0004123663,0.0009562743,0.001237164,0.002174329,0.006440183],"category_scores_gemma":[0.00161734,0.001198825,0.001682428,0.0006368157,0.001506114,0.001429406,0.0004132828,0.003300182,0.001160062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008891764,"about_ca_system_score_gemma":0.001083182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001479467,"about_ca_topic_score_gemma":0.0037569,"domain_scores_codex":[0.9993544,0.0003165521,0.00003508582,0.0001119602,0.00006577795,0.0001162047],"domain_scores_gemma":[0.9993526,0.0001915001,0.0001157262,0.00004585214,0.00004621454,0.0002481113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9745873,0.007023655,0.0001589721,0.0006663162,0.0005786464,0.00002499164,0.00002571597,0.000200646,0.003197578,0.00007445806,0.0005787234,0.01288294],"study_design_scores_gemma":[0.945169,0.0530652,0.0005397508,0.00001885795,0.0002570007,0.00002063121,0.000009667522,0.0002243801,0.0002869657,0.00005268981,0.0003439179,0.00001195603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766752,0.01132134,0.001176035,0.0009045581,0.001299167,0.003980356,0.001327235,0.0003069174,0.003009371],"genre_scores_gemma":[0.9749536,0.008418277,0.002290664,0.001477252,0.0009983232,0.004017677,0.001529776,0.00005594459,0.006258523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006440183,"threshold_uncertainty_score":0.02154458,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2440107260249871,"score_gpt":0.4720551641385096,"score_spread":0.2280444381135225,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}